Sudo Biosciences

Executive Summary

Sudo Biosciences is a clinical-stage biotechnology company pioneering first- and best-in-class small molecule TYK2 inhibitors for serious neurological and immunological diseases. Founded in 2020 and based in San Francisco, the company's lead candidate, SUDO-550, is a brain-penetrant allosteric TYK2 inhibitor currently in Phase 1 clinical development. By selectively targeting TYK2, Sudo aims to modulate key inflammatory pathways while minimizing systemic side effects, with an initial focus on conditions such as multiple sclerosis, psoriasis, and other autoimmune disorders. The company's strategy leverages deep expertise in kinase biology and structure-based drug design to address high unmet medical needs. With no approved brain-penetrant TYK2 inhibitors to date, Sudo's approach could offer a significant therapeutic advantage. The company is privately held and has not disclosed total funding or valuation, but its progress in Phase 1 positions it for potential value inflections as clinical data emerge.

Upcoming Catalysts (preview)

• H2 2026Phase 1 SUDO-550 safety and PK data readout55% success
• 2027Initiation of Phase 2 proof-of-concept trial in multiple sclerosis or psoriasis45% success
• TBDPotential partnership or licensing agreement for TYK2 program30% success